title: Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations.
abstract: The cardiovascular effects of DN-9693, a newly synthesized cyclic AMP phosphodiesterase inhibitor, and sulmazole were investigated in an isolated right atrial or left ventricular preparation which was cross-perfused with blood from another support dog. Each substance dose-dependently increased heart rate and decreased blood pressure of the support dog when administered i.v. The hypotensive effects of DN-9693 were about 40 times more potent than those of sulmazole. The positive chronotropic effect of DN-9693 was about 10 times more potent, but the maximal increase in heart rate was much less than that produced by sulmazole. Each substance dose-dependently increased the sinus rate, the right atrial and the left ventricular developed tension in isolated preparations when administered selectively into cannulated arteries. The effects of DN-9693 were about 10-30 times more potent than those of sulmazole, although the maximal positive chronotropic response to DN-9693 was significantly smaller. Positive chrono- and inotropic effects induced by both substances in the isolated, blood-perfused right atrial preparation were not inhibited by treatment with propranolol, but they were consistently attenuated by electrical stimulation of intramural vagal nerve fibers. These results suggest that DN-9693 and sulmazole produce cardiotonic effects by directly increasing the cyclic AMP level in the dog heart. DN-9693 possesses more potent cardiotonic and vasodilating effects than sulmazole, and has a smaller effect on heart rate.
authors.affiliation: Department of Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Akahane
authors.forename: Y
authors.initials: Y
authors.lastname: Furukawa
authors.forename: M
authors.initials: M
authors.lastname: Haniuda
authors.forename: Y
authors.initials: Y
authors.lastname: Karasawa
authors.forename: S
authors.initials: S
authors.lastname: Chiba
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003427:Cross Circulation; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*
chemical_list: D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011799:Quinazolines; C049662:1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3H)-one; D015105:3',5'-Cyclic-AMP Phosphodiesterases; C029758:sulmazole